Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

HJKC3-007: Outcomes of Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Asciminib and Other Tyrosine Kinase Inhibitors in Routine Clinical Practice

Blood (2023) 142 (Supplement 1): 7434.

https://doi.org/10.1182/blood-2023-188683

Published: 2023

Journal Articles

The Lymphocyte Subsets Activation Profiles in Peripheral Blood May Contribute to the Diagnosis of Natural Killer/T-Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis

Yanxia He, Yan Gao, Xiaoxiao Wang, Bing Bai, Zhiming Li, Haixia He, Liqin Ping, Cheng Huang, Haoqing Chen, Huiqiang Huang

Blood (2023) 142 (Supplement 1): 6218.

https://doi.org/10.1182/blood-2023-186496

Published: 2023

Journal Articles

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

Blood (2023) 142 (Supplement 1): 7420.

https://doi.org/10.1182/blood-2023-179963

Published: 2023

Journal Articles

High-Dose Methotrexate, Ibrutinib and Temozolomide (MIT) for the Treatment of Newly Diagnosed Primary Central Nervous System Lymphoma: A Multi-Center Prospective Phase II Study

Liqin Ping, Xiaoxiao Wang, Yan Gao, Bing Bai, He Huang, Linbo Cai, Hui Zhou, Changguo Shan, Zhiming Li, Mingyao Lai, Haixia He, Cheng Huang, Haoqing Chen, Ru Feng, Huiqiang Huang

Blood (2023) 142 (Supplement 1): 3086.

https://doi.org/10.1182/blood-2023-185212

Published: 2023

Journal Articles

XPO1 Inhibitor (ATG-010) Plus GemOx Regimen for Heavily Pretreated Patients with Relapsed or Refractory (R/R) T and NK-Cell Lymphoma：Updates of the Phase Ib Touch Study

Huiqiang Huang, Yan Gao, Huilai Zhang, Keshu Zhou, Jianqiu Wu, Zhen Cai, Hongmei Jing, LEI Fan, Sai Lou, Yizhou Fei, Aihua Wang, Kevin Lynch

Blood (2022) 140 (Supplement 1): 6554–6555.

https://doi.org/10.1182/blood-2022-165797

Published: 2022

Journal Articles

Frontline Treatment with Zanubrutinib Plus Rituximab (ZR) Followed By Short Course R-Dhaox Shows Potent Efficacy in Patients with Mantle Cell Lymphoma (MCL) - Preliminary Results of Phase II CHESS Clinical Trial

Qingqing Cai, Yi Xia, Panpan Liu, Yuchen Zhang, Huiqiang Huang, Yan Gao, Guowei Li, Xiuhua Sun, Xueyi Pan

Blood (2022) 140 (Supplement 1): 9356–9357.

https://doi.org/10.1182/blood-2022-166237

Published: 2022

Journal Articles

A Prospective Study of Methotrexate in Combination with Ibrutinib and Temozolomide (MIT) in Newly Diagnosed Primary CNS Lymphoma

Xiaoxiao Wang, Changguo Shan, He Huang, Zhiming Li, Hui Zhou, Yan Gao, Shanshan Yu, Xiaoyu Hong, Mingyao Lai, Chao Yang, Yang Shao, Linbo Cai, Huiqiang Huang

Blood (2022) 140 (Supplement 1): 6606–6607.

https://doi.org/10.1182/blood-2022-169608

Published: 2022

Journal Articles

Combination of Decitabine and ATRA in Newly Diagnosed Myelodysplastic Syndromes Subtype EB-Interim Analysis of a Multicenter, Randomized, Open-Label Trial

Xinping Zhou, Fanjun Meng, Yanjuan Lin, Zheng Ge, Yuemin Kuang, Lu Wang, Jin Zhang, Hai Cheng, Yan Gao, Yulu Tian, Li Huang, Jie Jin, Hongyan Tong

Blood (2021) 138 (Supplement 1): 539.

https://doi.org/10.1182/blood-2021-149326

Published: 2021

Journal Articles

XPO1 Inhibitor (ATG-010) Plus Chemotherapy per Investigator's Choice for Heavily Pretreated Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Extranodal NK/T-Cell Lymphoma (ENKTL)：Preliminary Results from a Multicenter, Single-Arm, Phase Ib Study (TOUCH Trial)

Huiqiang Huang, Yan Gao, Huilai Zhang, Keshu Zhou, Jianqiu Wu, Zhen Cai, Hongmei Jing, Lei Fan, Sai Lou, Yizhou Fei, Aihua Wang, Kevin Lynch

Blood (2021) 138 (Supplement 1): 2452.

https://doi.org/10.1182/blood-2021-147100

Published: 2021

Journal Articles

Preliminary Results of a Phase II Study of Methotrexate in Combination with Ibrutinib and Temozolomide (MIT) in Newly Diagnosed Primary CNS Lymphoma

Xiaoxiao Wang, Yan Gao, Shanshan Yu, Bing Bai, Qiuxiang Ou, Liuqing Zhu, He Huang, Hui Zhou, Yang Shao, Linbo Cai, Hui-qiang Huang

Blood (2021) 138 (Supplement 1): 2481.

https://doi.org/10.1182/blood-2021-150658

Published: 2021

Journal Articles

Single-cell transcriptomics dissects hematopoietic cell destruction and T-cell engagement in aplastic anemia

Caiying Zhu, Yu Lian, Chenchen Wang, Peng Wu, Xuan Li, Yan Gao, Sibin Fan, Lanlan Ai, Liwei Fang, Hong Pan, Tao Cheng, Jun Shi, Ping Zhu

Blood (2021) 138 (1): 23–33.

https://doi.org/10.1182/blood.2020008966

Published: 2021

Includes: Supplemental data

Journal Articles

Safety and Efficacy of Mitoxantrone Hydrochloride Liposome in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma and Extranodal NK/T-Cell Lymphoma: A Prospective, Single-Arm, Open-Label, Multi-Center, Phase Ⅱ Clinical Trial

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-141752

Published: 2020

Journal Articles

Association of Circulating Tumor DNA from the Cerebrospinal Fluid with High-Risk CNS Involvement in Patients with Diffuse Large B-Cell Lymphoma

Xiaoxiao Wang, Yan Gao, MD PhD, Changguo Shan, Mingyao Lai, Haixia He, Bing Bai, Li-qin Ping, Qixiang Rong, Ruyu Ai, Lei Wen, Zhaoming Zhou, Ruoying Yu, Qiuxiang Ou, Xue Wu, Xiaoxia Wang, Yang Shao, Linbo Cai, Hui-qiang Huang

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-134804

Published: 2020

Journal Articles

Anti-PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single-Arm, Phase Ib/II Trial (SCENT)

Yan Gao, MD PhD, Huiqiang Huang, MDPhD, Xiaoxiao Wang, Bing Bai, Liling Zhang, MD PhD, Yin Xiao, Xinxiu Liu, Wenyu Li, PhD, Wei Xu, MD PhD, Ru Feng, Yu Chen, Huijing Wu, Jibin Li, Xue Wu

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-134665

Published: 2020

Journal Articles

Safety and Preliminary Efficacy of Sintilimab Plus P-Gemox (Pegaspargase, Gemcitabine and Oxaliplatin) Regimen As First-Line Treatment for Patients with Advanced Extranodal Natural Killer/T Cell Lymphoma, Nasal Type: An Open-Label, Multicenter, Phase 2 Study

Qingqing Cai, PhD, Huiqiang Huang, MDPhD, Panpan Liu, MD PhD, Hui Zhou, MD PhD, Yajun Li, MD PhD, Yujing Zhang, MD PhD, Lixia Lu, MD PhD, Yan Gao, MD PhD, Xuanye Zhang, MDPhD, Yi Xia, MD PhD, Jun Cai, BMBS, Ning Su, MM, Shuyun Ma, MM, Hang Yang, MD PhD, Yu Fang, BMBS

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-136949

Published: 2020

Journal Articles

Defective Early B Cell Tolerance in Primary Immune Thrombocytopenia

Xinyi Zuo, Zi Sheng, MDcal student, Yan Gao, MDcal student, Ming Hou, MDPhD, Song Li, PhD, Jun Peng, MDPhD

Blood (2017) 130 (Supplement 1): 3635.

https://doi.org/10.1182/blood.V130.Suppl_1.3635.3635

Published: 2017

Journal Articles

The Therapeutic Response of Chidamide Was Associated with Elevated H3 Acetylation Level in Patients with Refractory/Relapsed Non-Hodgkin Lymphoma (R/R-NHL)

Hui-qiang Huang, MD PhD, Pengfei Li, Yan Gao, Bai Bing, Wang Xiaoxiao, Rong Qixiang, Su Li, Wenqi Jiang

Blood (2017) 130 (Supplement 1): 4080.

https://doi.org/10.1182/blood.V130.Suppl_1.4080.4080

Published: 2017

Journal Articles

Pegaspargase Plus Gemcitabine, Oxaliplatin(P-Gemox) and Thalidomide Versus Aspermetdex Regimen for the Patients with Early or Advanced/Relapsed Extranodal Natural Killer/T Cell Lymphoma: Interim Analysis of a Prospective,Multicenter, Randomized, Phase III Non-Inferiority Clinical Trial

Yan Gao, Huiqiang Huang, MD, Yujing Zhang, Hang Su, Xiaoxiao Wang, Bing Bai, Yunhong Huang, Yuhuan Gao, Liping Su, MD, Xiaoxia Chu, Wenyu Li, Junyi Zhang, Qiaohua Zhang, Liansheng Zhang, Xiaohua Hu, Liqun Zou, Zhiming Li, Wenqi Jiang, MD PhD

Blood (2016) 128 (22): 1819.

https://doi.org/10.1182/blood.V128.22.1819.1819

Published: 2016

Journal Articles

Longterm Outcome of Induction Chemotherapy of P-Gemox Regimen Followed By Extensive Involved-Field Radiotherapy(EIFRT) for Newly Diagnosed Stage I/II Extranodal Natural Killer/T-Cell Lymphoma---a Single Center Experience

Huiqiang Huang, MD, Yan Gao, XiaoXiao Wang, Qingqing Cai, MD, QiChun Cai, Bing Bai, Zheng Yan, Wenqi Jiang, Zhongjun Xia, MD, ZhiMing Li

Blood (2015) 126 (23): 3936.

https://doi.org/10.1182/blood.V126.23.3936.3936

Published: 2015

Journal Articles

Clinical Outcome of P-Gemox ( Pegaspargase, Gemcitabine, Oxaliplatin ) for the Patients with Newly Diagnosed Stage III/IV or Relapsed/Refractory Extranodal Natural Killer/T Cell Lymphoma

Huiqiang Huang, MD, Yan Gao, XiaoXiao Wang, Qingqing Cai, MD, QiChun Cai, Bing Bai, Wei Zhao, Zheng Yan, Wenqi Jiang, MD PhD, Zhongjun Xia, MD, ZhiMing Li

Blood (2015) 126 (23): 1521.

https://doi.org/10.1182/blood.V126.23.1521.1521

Published: 2015

NARROW

HJKC3-007: Outcomes of Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Asciminib and Other Tyrosine Kinase Inhibitors in Routine Clinical Practice

The Lymphocyte Subsets Activation Profiles in Peripheral Blood May Contribute to the Diagnosis of Natural Killer/T-Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

High-Dose Methotrexate, Ibrutinib and Temozolomide (MIT) for the Treatment of Newly Diagnosed Primary Central Nervous System Lymphoma: A Multi-Center Prospective Phase II Study

XPO1 Inhibitor (ATG-010) Plus GemOx Regimen for Heavily Pretreated Patients with Relapsed or Refractory (R/R) T and NK-Cell Lymphoma：Updates of the Phase Ib Touch Study

Frontline Treatment with Zanubrutinib Plus Rituximab (ZR) Followed By Short Course R-Dhaox Shows Potent Efficacy in Patients with Mantle Cell Lymphoma (MCL) - Preliminary Results of Phase II CHESS Clinical Trial

A Prospective Study of Methotrexate in Combination with Ibrutinib and Temozolomide (MIT) in Newly Diagnosed Primary CNS Lymphoma

Combination of Decitabine and ATRA in Newly Diagnosed Myelodysplastic Syndromes Subtype EB-Interim Analysis of a Multicenter, Randomized, Open-Label Trial

XPO1 Inhibitor (ATG-010) Plus Chemotherapy per Investigator's Choice for Heavily Pretreated Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Extranodal NK/T-Cell Lymphoma (ENKTL)：Preliminary Results from a Multicenter, Single-Arm, Phase Ib Study (TOUCH Trial)

Preliminary Results of a Phase II Study of Methotrexate in Combination with Ibrutinib and Temozolomide (MIT) in Newly Diagnosed Primary CNS Lymphoma

Single-cell transcriptomics dissects hematopoietic cell destruction and T-cell engagement in aplastic anemia

Safety and Efficacy of Mitoxantrone Hydrochloride Liposome in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma and Extranodal NK/T-Cell Lymphoma: A Prospective, Single-Arm, Open-Label, Multi-Center, Phase Ⅱ Clinical Trial

Association of Circulating Tumor DNA from the Cerebrospinal Fluid with High-Risk CNS Involvement in Patients with Diffuse Large B-Cell Lymphoma

Anti-PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single-Arm, Phase Ib/II Trial (SCENT)

Safety and Preliminary Efficacy of Sintilimab Plus P-Gemox (Pegaspargase, Gemcitabine and Oxaliplatin) Regimen As First-Line Treatment for Patients with Advanced Extranodal Natural Killer/T Cell Lymphoma, Nasal Type: An Open-Label, Multicenter, Phase 2 Study

Defective Early B Cell Tolerance in Primary Immune Thrombocytopenia

The Therapeutic Response of Chidamide Was Associated with Elevated H3 Acetylation Level in Patients with Refractory/Relapsed Non-Hodgkin Lymphoma (R/R-NHL)

Pegaspargase Plus Gemcitabine, Oxaliplatin(P-Gemox) and Thalidomide Versus Aspermetdex Regimen for the Patients with Early or Advanced/Relapsed Extranodal Natural Killer/T Cell Lymphoma: Interim Analysis of a Prospective,Multicenter, Randomized, Phase III Non-Inferiority Clinical Trial

Longterm Outcome of Induction Chemotherapy of P-Gemox Regimen Followed By Extensive Involved-Field Radiotherapy(EIFRT) for Newly Diagnosed Stage I/II Extranodal Natural Killer/T-Cell Lymphoma---a Single Center Experience

Clinical Outcome of P-Gemox ( Pegaspargase, Gemcitabine, Oxaliplatin ) for the Patients with Newly Diagnosed Stage III/IV or Relapsed/Refractory Extranodal Natural Killer/T Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only